Gu Kang Mo, Shin Jong Wook, Park In Won
Division of Allergy and Pulmonary Medicine, Department of Internal Medicine, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea.
Tuberc Respir Dis (Seoul). 2014 Dec;77(6):274-8. doi: 10.4046/trd.2014.77.6.274. Epub 2014 Dec 31.
Antiphospholipid syndrome (APS) is an acquired systemic autoimmune disorder characterized by a combination of clinical criteria, including vascular thrombosis or pregnancy morbidity and elevated antiphospholipid antibody titers. It is one of the causes of deep vein thrombosis and pulmonary embolism that can be critical due to the mortality risk. Overall recurrence of thromboembolism is very low with adequate anticoagulation prophylaxis. The most effective treatment to prevent recurrent thrombosis is long-term anticoagulation. We report on a 17-year-old male with APS, who manifested blue toe syndrome, deep vein thrombosis, pulmonary thromboembolism, and cerebral infarction despite adequate long-term anticoagulation therapy.
抗磷脂综合征(APS)是一种获得性全身性自身免疫性疾病,其特征为临床标准的组合,包括血管血栓形成或妊娠并发症以及抗磷脂抗体滴度升高。它是深静脉血栓形成和肺栓塞的病因之一,由于存在死亡风险,可能非常严重。通过充分的抗凝预防,血栓栓塞的总体复发率非常低。预防复发性血栓形成的最有效治疗方法是长期抗凝。我们报告一例17岁患有抗磷脂综合征的男性患者,尽管进行了充分的长期抗凝治疗,仍出现了蓝趾综合征、深静脉血栓形成、肺血栓栓塞和脑梗死。